Back to top
more

Sage Therapeutics (SAGE)

(Real Time Quote from BATS)

$14.63 USD

14.63
276,988

+0.94 (6.87%)

Updated Apr 29, 2024 01:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for SAGE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Sage Therapeutics, Inc. [SAGE]

Reports for Purchase

Showing records 101 - 120 ( 152 total )

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 101

10/16/2020

Daily Note

Pages: 4

Interim SHORELINE Data Points in the Right Direction; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 102

10/15/2020

Company Report

Pages: 9

How Long - SHORELINE Attempts To Answer The Question

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 103

09/14/2020

Daily Note

Pages: 5

Key Takeaways from Sage FutureCast; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 104

09/11/2020

Daily Note

Pages: 8

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 105

09/11/2020

Company Report

Pages: 14

Upgrading to Outperform; See Reason For Optimism On Exposure

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 50.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 106

09/01/2020

Daily Note

Pages: 11

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 107

09/01/2020

Daily Note

Pages: 17

What Does the FutureCast Hold for SAGE? R-D Day Preview

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 50.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 108

08/12/2020

Company Report

Pages: 5

Zuranolone Studies Ramp-Up, While Zulresso Continues to Experience Slow Sales; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 109

08/10/2020

Daily Note

Pages: 9

Trials March Along Across Multiple Fronts

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 110

05/11/2020

Company Report

Pages: 5

It''s All About the Pipeline as Covid-19 Strikes Another Blow to Zulresso; Reiterate Neutral, Target to $76

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 111

05/08/2020

Daily Note

Pages: 19

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 112

05/07/2020

Company Report

Pages: 8

Moving to Neutral; We See Zuranolone As Active, But Valuation Stretched

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 113

04/17/2020

Industry Report

Pages: 16

Don''t Sleep on New Mechanisms for MDD: A Look at GABA Modulation and Orexin-2 Antagonists

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 50.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 114

04/13/2020

Daily Note

Pages: 25

Looking Beyond COVID: 1Q20 Commercial Preview

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 75.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 115

04/13/2020

Daily Note

Pages: 25

Looking Beyond COVID: 1Q20 Commercial Preview

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 75.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 116

04/08/2020

Daily Note

Pages: 4

Bending to the Realities Facing Zulresso, Though Development Timelines for Pipeline Hold for Now; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 117

04/08/2020

Company Report

Pages: 9

Restructuring Rears Its Head, But A Necessary Evil

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 118

04/08/2020

Daily Note

Pages: 7

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 119

03/19/2020

Daily Note

Pages: 4

Aiming to Accentuate Zuranolone’s Rapid Onset; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 120

03/18/2020

Company Report

Pages: 7

With Map In Hand, They''re Running Down The Road Now

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party